Quick Answer
Under US GAAP (ASC 730), research and development costs are generally expensed as incurred. The journal entry is a debit to R&D Expense and a credit to Cash or Accounts Payable. Under IFRS, research costs are expensed but development costs may be capitalized once certain criteria are met under IAS 38. This article walks through every common R&D journal entry scenario including materials, payroll, overhead allocation, and IFRS capitalization.
What Are R&D Expenses?
Research and development (R&D) expenses represent the costs a company incurs to create new products, improve existing ones, or develop new processes and technologies. These costs include salaries of R&D staff, raw materials consumed in experimentation, consulting fees, depreciation of lab equipment, and overhead allocated to R&D activities.
In the United States, ASC 730 requires that most R&D costs be expensed in the period they are incurred. This conservative approach reflects the high uncertainty around whether R&D efforts will generate future economic benefits. Internationally, IAS 38 under IFRS takes a bifurcated approach: the research phase is expensed, but development costs can be capitalized once technical feasibility, market viability, and other criteria are demonstrated.
Basic R&D Expense Journal Entry
The most common entry for R&D spending is straightforward — record the expense and credit the corresponding payable or cash account.
When R&D Is Paid in Cash
Dr. R&D Expense $50,000
Cr. Cash $50,000
(To record cash payment for R&D activities)
When R&D Is Purchased on Account
Dr. R&D Expense $35,000
Cr. Accounts Payable $35,000
(To record R&D costs purchased on credit)
R&D Payroll Journal Entries
Employee compensation is often the largest component of R&D spending. When R&D staff are paid, the payroll entry includes gross wages, employer payroll taxes, and benefits.
Accruing R&D Payroll
Dr. R&D Expense $80,000
Cr. Accrued Payroll $64,000
Cr. Withholding Tax Payable $10,000
Cr. FICA Tax Payable $6,000
(To accrue R&D staff payroll for the period)
For more on payroll journal entries, see our guide to journal entries for payroll.
Employer Payroll Taxes for R&D Staff
Dr. R&D Expense $6,120
Cr. FICA Tax Payable (employer) $4,896
Cr. FUTA Payable $434
Cr. SUTA Payable $790
(To record employer payroll taxes for R&D employees)
R&D Materials and Supplies
When raw materials are consumed in R&D, the entry depends on whether the materials were previously inventoried or purchased specifically for the R&D project.
Materials Purchased and Used Immediately
Dr. R&D Expense $12,500
Cr. Cash / Accounts Payable $12,500
(To record purchase and use of R&D materials)
Materials Withdrawn from Inventory
Dr. R&D Expense $8,200
Cr. Inventory $8,200
(To transfer inventory to R&D consumption)
Depreciation of R&D Equipment
When lab equipment or specialized machinery is used in R&D, its depreciation is classified as R&D expense rather than general depreciation.
Dr. R&D Expense $4,500
Cr. Accumulated Depreciation — Equipment $4,500
(To record depreciation on R&D lab equipment)
This differs from general depreciation entries. See our article on journal entries for depreciation for the standard approach.
R&D with Prepaid Expenses
Sometimes a company prepays for R&D services (such as a year-long lab lease or retainer for contract researchers). The prepayment is initially recorded as a prepaid asset and then amortized to R&D expense over the service period.
Initial Prepayment
Dr. Prepaid R&D $24,000
Cr. Cash $24,000
(To prepay annual R&D lab lease)
Monthly Amortization
Dr. R&D Expense $2,000
Cr. Prepaid R&D $2,000
(To record monthly amortization of prepaid R&D costs)
For more on prepaid expense entries, see journal entries for prepaid expenses.
IFRS Capitalization of Development Costs (IAS 38)
Under IFRS, once a project moves from the research phase to the development phase and meets all six IAS 38 criteria, development costs are capitalized as an intangible asset rather than expensed.
The Six IAS 38 Capitalization Criteria
- Technical feasibility of completing the intangible asset
- Intention to complete and use or sell the asset
- Ability to use or sell the intangible asset
- Probable future economic benefits
- Adequate technical, financial, and other resources to complete
- Reliable measurement of expenditure attributable to the asset
Capitalizing Development Costs Under IFRS
Dr. Development Asset (Intangible) $45,000
Cr. Cash / Accounts Payable $45,000
(To capitalize development costs meeting IAS 38 criteria)
Amortizing the Capitalized Development Asset
Once the asset is available for use, amortize it over its useful life:
Dr. Amortization Expense $3,750
Cr. Accumulated Amortization — Intangibles $3,750
(To amortize development asset over 12-month useful life)
R&D Tax Credit Considerations
Many companies qualify for R&D tax credits that reduce income tax expense. The credit itself does not affect the R&D expense entry — it is recognized when the tax return is filed or estimated. For detailed guidance, see our R&D tax credit guide for small business.
When the R&D credit is recognized, the entry reduces income tax expense:
Dr. Income Tax Payable $15,000
Cr. Income Tax Expense $15,000
(To record R&D tax credit reducing income tax liability)
Contracted R&D Services
When a company hires an external firm to perform R&D, the costs are treated the same as internal R&D — expensed as incurred under US GAAP.
Dr. R&D Expense $60,000
Cr. Accounts Payable $60,000
(To record contracted R&D services on account)
For related entries, see journal entries for professional fees.
Key Takeaways
- Under US GAAP (ASC 730), all R&D costs are expensed as incurred — no capitalization permitted
- Under IFRS (IAS 38), research costs are expensed but development costs can be capitalized once six criteria are met
- Common R&D debits include salaries, materials, depreciation, contracted services, and overhead
- R&D tax credits are recorded separately as a reduction to income tax expense, not to R&D expense
- Prepaid R&D costs are initially recorded as assets and amortized to expense over the service period
- Always clearly label R&D entries in your chart of accounts for clean financial statement disclosure
